Up to now, researchers believed that lung remodeling follows an autoimmune inflammation triggered by components of the extracellular matrix. In August, British scientists provided a more accurate view of the processes in the lung tissue, opening up a way to optimise failed mid-stage clinical candidates.
Newron bags €40m EIB loan
Latest NewsThe EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to €40m to support the development of the company’s late-stage pipeline.
TES Pharma presents new treatment approach towards AKI and NALFD
Latest NewsTES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.
Asthma needs to be targeted more specifically
BackgroundUp to now, researchers believed that lung remodeling follows an autoimmune inflammation triggered by components of the extracellular matrix. In August, British scientists provided a more accurate view of the processes in the lung tissue, opening up a way to optimise failed mid-stage clinical candidates.
MEPs vote for ban of single-use plastics
Latest NewsThe European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021.
Zelluna appoints new CFO
AppointmentsZelluna Immunotherapy has announced the appointment of Geir Christian Melen as chief financial officer (CFO).
Diversifying into oncology if ROI on bugs is too low
OpinionBig Pharma’s interest in R&D on anti-infectives declined when other areas like oncology began offering higher returns. A few biotechs mirror pharma (Basilea, Idorsia and Polyphor), but could stay hidden gems.
AstraZeneca and Innate Pharma in US$5bn oncology deal
Latest NewsAstraZeneca plc has extended its immunoncology pipeline by an extension of its partnership with French Innate Pharma SA.
Takeda strikes US$640m deal with Enterome
Latest NewsFrench Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m.
EMA recommends four biologicals for market
Latest NewsThe European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.
Companies at EFIB set to drive the bioeconomy
Latest NewsIndustrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately.